Vascular and renal benefits are additive using intensive blood pressure control and incremental glucose control in type 2 diabetic patients.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004232:Diuretics / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005907:Gliclazide / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007190:Indapamide / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects*; D020913:Perindopril / Q000627:therapeutic use; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D004232:Diuretics; D007004:Hypoglycemic Agents; D007190:Indapamide; D005907:Gliclazide; D020913:Perindopril